Table 1.
Characteristics of the rheumatoid arthritis patient cohorts
|
Characteristics |
All RA patients |
Longitudinal etanercept study |
|---|---|---|
| ( N = 75) | ( N = 16) | |
| Median age, years (range) |
57.0 (23 to 83) |
56.0 (41 to 66) |
| Female/male (n) |
55/20 |
10/6 |
| Median disease duration, years (range) |
7.0 (1 to 57) |
2 (1 to 13) |
| RF-positive (%) |
77.0 |
68.8 |
| Anti-CCP-positive (%) |
75.8 |
93.8 |
| Median CRP, mg/dl (range) |
3.53 (0 to 113) |
4.40 (0.5 to 21.1) |
| DMARDs (n) |
|
|
| Methotrexate |
42 |
13 |
| Azathioprine |
1 |
0 |
| Leflunomide |
4 |
1 |
| Anti-TNF |
7 |
0 |
| Anti-TNF + MTX |
2 |
0 |
| Abatacept |
1 |
0 |
| Hydroxychloroquine + MTX |
1 |
1 |
| Cyclosporin A |
1 |
0 |
| Cyclosporin A + MTX |
1 |
0 |
| Tocilizumab |
1 |
0 |
| Rituximab |
1 |
0 |
| Without | 13 | 1 |
aCCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor.